Characteristics of ATLL
| Clinical characteristic . | No. (n = 135) . | % . |
|---|---|---|
| Age, y, median (range) | 67 (35-90) | — |
| Sex, male/female | 76/59 | 56/44 |
| ECOG PS, 2-4 | 43/132 | 33 |
| Shimoyama classification | ||
| Smoldering type | 2/111 | 2 |
| Acute type | 56/111 | 51 |
| Lymphoma type | 53/111 | 48 |
| B symptom | 42/130 | 32 |
| Elevated LDH | 77 | 57 |
| Hypercalcemia | 21 | 16 |
| Elevated CRP | 80/132 | 61 |
| Ann Arbor stage, III or IV | 113/134 | 84 |
| Peripheral blood involvement | 70/132 | 53 |
| Bone marrow involvement | 30/106 | 28 |
| Skin lesion | 23/134 | 17 |
| WBC, ×109/L, median (range) | 6.6 (1.2-97.1) | — |
| Hemoglobin, g/dL, median (range) | 12.9 (6.3-18.6) | — |
| Platelets, ×109/L, median (range) | 213 (19-840) | — |
| IPI, high-intermediate or more | 78/129 | 61 |
| JCOG-PI, high | 52/132 | 39 |
| Treatment | ||
| Chemotherapy | 117/133 | 88 |
| Radiation | 14/131 | 11 |
| Transplantation | 19/131 | 15 |
| No chemotherapy or radiotherapy | 13/133 | 10 |
| CR or CR(u) | 35/116 | 30 |
| Clinical characteristic . | No. (n = 135) . | % . |
|---|---|---|
| Age, y, median (range) | 67 (35-90) | — |
| Sex, male/female | 76/59 | 56/44 |
| ECOG PS, 2-4 | 43/132 | 33 |
| Shimoyama classification | ||
| Smoldering type | 2/111 | 2 |
| Acute type | 56/111 | 51 |
| Lymphoma type | 53/111 | 48 |
| B symptom | 42/130 | 32 |
| Elevated LDH | 77 | 57 |
| Hypercalcemia | 21 | 16 |
| Elevated CRP | 80/132 | 61 |
| Ann Arbor stage, III or IV | 113/134 | 84 |
| Peripheral blood involvement | 70/132 | 53 |
| Bone marrow involvement | 30/106 | 28 |
| Skin lesion | 23/134 | 17 |
| WBC, ×109/L, median (range) | 6.6 (1.2-97.1) | — |
| Hemoglobin, g/dL, median (range) | 12.9 (6.3-18.6) | — |
| Platelets, ×109/L, median (range) | 213 (19-840) | — |
| IPI, high-intermediate or more | 78/129 | 61 |
| JCOG-PI, high | 52/132 | 39 |
| Treatment | ||
| Chemotherapy | 117/133 | 88 |
| Radiation | 14/131 | 11 |
| Transplantation | 19/131 | 15 |
| No chemotherapy or radiotherapy | 13/133 | 10 |
| CR or CR(u) | 35/116 | 30 |
| Pathological characteristics . | No. (n = 135) . | % . |
|---|---|---|
| Morphological classification | ||
| Small cell variant | 3 | 2 |
| Medium cell variant | 28 | 21 |
| Large cell variant | 57 | 42 |
| Hodgkin like variant | 2 | 2 |
| Anaplastic variant | 9 | 7 |
| Pleomorphic variant | 36 | 27 |
| IHC | ||
| nPD-L1 positive | 10 | 7 |
| nPD-L1 negative | 125 | 93 |
| mPD-L1 positive | 79 | 59 |
| PD-L1 positive | 46 | 34 |
| Neoplastic cells | ||
| PD-1, positive | 25 | 19 |
| CD30, positive | 36 | 27 |
| FoxP3, positive | 35 | 26 |
| CCR4, positive | 126 | 93 |
| PD-1-positive TIL, counts/HPF, average (range) | 2.4 (0-38.4) | — |
| Pathological characteristics . | No. (n = 135) . | % . |
|---|---|---|
| Morphological classification | ||
| Small cell variant | 3 | 2 |
| Medium cell variant | 28 | 21 |
| Large cell variant | 57 | 42 |
| Hodgkin like variant | 2 | 2 |
| Anaplastic variant | 9 | 7 |
| Pleomorphic variant | 36 | 27 |
| IHC | ||
| nPD-L1 positive | 10 | 7 |
| nPD-L1 negative | 125 | 93 |
| mPD-L1 positive | 79 | 59 |
| PD-L1 positive | 46 | 34 |
| Neoplastic cells | ||
| PD-1, positive | 25 | 19 |
| CD30, positive | 36 | 27 |
| FoxP3, positive | 35 | 26 |
| CCR4, positive | 126 | 93 |
| PD-1-positive TIL, counts/HPF, average (range) | 2.4 (0-38.4) | — |
CRP, C-reactive protein; CR, complete response/remission; CR(u), uncertain complete response/remission; ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, international prognostic index; LDH, lactate dehydrogenase; WBC, white blood cell.